| NCT ID | NCT07343115 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Systemic Scleroderma |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-09-02 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-09-02 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Studying familial forms of systemic scleroderma offers several advantages: 1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms); 2. To identify potential molecular markers predictive of disease progression; 3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.
Eligibility Criteria
Inclusion Criteria: * Adult subjects (≥ 18 years of age) * Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities * At least one first-degree relative with systemic scleroderma meeting the same criteria Exclusion Criteria: \- Subject who has expressed opposition to participating in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07343115 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Systemic Scleroderma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07343115 currently recruiting?
Yes, NCT07343115 is actively recruiting participants. Contact the research team at aurelien.guffroy@chru-strasbourg.fr for enrollment information.
Where is the NCT07343115 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07343115 clinical trial?
NCT07343115 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 20 participants.